Creating a new oral antibiotic to treat drug-resistant gonorrhea
Official title: Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea
Funded at Aimmax Therapeutics, INC. · NIH-10873308 · Data updated 2026-11-12
This study is testing a new oral antibiotic that aims to effectively treat drug-resistant gonorrhea and chlamydia in one easy-to-take pill, making it simpler for people to stick to their treatment and helping tackle the rising issue of antibiotic resistance.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aimmax Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | August 8, 2022 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $999,991 |
| NIH project number | 5R44AI170150-03 |
| Project ID | NIH-10873308 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with gonorrhea, particularly those with drug-resistant strains or co-infections with chlamydia.
✕Less likely to help
Patients who do not have gonorrhea or chlamydia infections will not benefit from this research.
What this research studies
This research focuses on developing a novel oral antibiotic specifically designed to combat drug-resistant strains of gonorrhea, a sexually transmitted infection. The approach aims to create a medication that is effective against both Neisseria gonorrhoeae and Chlamydia trachomatis, which often co-infect individuals. By providing a single oral treatment option, the research seeks to improve patient adherence to therapy and reduce the need for multiple medications. The study is critical as it addresses the growing public health threat posed by antibiotic-resistant gonorrhea.
Why it matters
Potential benefit: If successful, this research could provide a more effective and convenient treatment option for patients suffering from gonorrhea and chlamydia infections.
How similar studies have gone: While antibiotic resistance is a significant challenge, this approach of developing a novel oral antibiotic for gonorrhea is relatively novel and has not been extensively tested in similar studies.
Where this research is happening
-
Aimmax Therapeutics, INC.
Durham, United States Active
Researchers
- Principal investigator: Wang, Laurene — Aimmax Therapeutics, INC.
- Study coordinator: Wang, Laurene
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.